Abstract
Background Immune reconstitution inflammatory syndrome (IRIS) is a set of conditions, characterized by findings of inflammation, which occur in HIV-infected patients after initiation of antiretroviral therapy (ART). It is believed to result from an overly exuberant response to residual opportunistic pathogens by the newly reconstituted immune system. Specific manifestations of IRIS depend upon the pathogen being targeted, but among the variants of IRIS, Kaposi's sarcoma-associated IRIS (KS-IRIS) is one of the least understood – especially in resource-limited settings where KS is epidemic. Now that ART is becoming available in sub-Saharan Africa, we have hypothesized that KS-IRIS is likely to be most relevant in this region. This is because of the high prevalence of AIDS-related KS in sub-Saharan Africa (i.e., large number of patients with AIDS-KS initiating ART) and because of factors that theoretically may predispose to KS-IRIS, specifically higher KS lesion burden and lower pre-ART CD4+ T cell count.
Highlights
Immune reconstitution inflammatory syndrome (IRIS) is a set of conditions, characterized by findings of inflammation, which occur in HIV-infected patients after initiation of antiretroviral therapy (ART)
That ART is becoming available in sub-Saharan Africa, we have hypothesized that Kaposi's sarcoma-associated immune reconstitution inflammatory syndrome (KS-IRIS) is likely to be most relevant in this region
This is because of the high prevalence of AIDS-related KS in sub-Saharan Africa and because of factors that theoretically may predispose to KS-IRIS, higher KS lesion burden and lower pre-ART CD4+ T cell count
Summary
Kaposi's sarcoma-associated immune reconstitution inflammatory syndrome (KS-IRIS) in Africa: initial findings from a prospective evaluation. Address: 1University of California, San Francisco; California, USA, 2Infectious Diseases Institute, Kampala, Uganda, 3Uganda Cancer Institute, Kampala, Uganda and 4Uganda Virus Research Institute, Entebbe, Uganda. Published: 17 June 2009 Infectious Agents and Cancer 2009, 4(Suppl 2):O17 doi:10.1186/1750-9378-4-S2-O17. phlettmpe:/n/wt>wmeePnrtorcale.ceodmin/gcsoonftethnet/p1d1ft/h17In5t0e-r9n3a7ti8o-n4a-Sl 2C-oinnfofe.prednf MAIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research Publication of this supplement was made possible with support from the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health. Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
